FDA Expands Approval for Amgen's Nexavar

Amgen's (NASDAQ: AMGN  ) cancer drug Nexavar is going to reach a broader market. Today, the Food and Drug Administration widened its approval for the drug to include its use in the treatment of several forms of late-stage differentiated thyroid cancer. The decision follows a priority review by the regulator, a process reserved for treatments that "may offer a significant improvement in treatment over existing options," in Amgen's words.

The thyroid is a gland located in the neck. Nexavar functions by inhibiting multiple proteins in cancer cells. This limits the growth and division of such cells.

There is a patient base for the drug. According to the FDA, for 2013 around 60,220 Americans will be diagnosed with thyroid cancer. Of that number, roughly 1,850 will die from it.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2740495, ~/Articles/ArticleHandler.aspx, 4/19/2014 1:43:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement